An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the changes in ALT to baseline among
patients with non-alcoholic fatty liver disease (NAFLD) following the 3-month treatment of 3
different dosing regimens of SNP-612. The secondary objectives will be to compare the changes
in other liver function tests, cytokeratin-18 (CK-18) fragment level and adverse event /
serious adverse event rates.